āđ€āļāļĩāđˆāļĒāļ§āļāļąāļšāļ•āļ­āļ™āļ™āļĩāđ‰

āļ āļēāļĐāļēāļ­āļąāļ‡āļāļĪāļĐ
āļŠāļŦāļĢāļąāļāļ­āđ€āļĄāļĢāļīāļāļē

āļŠāļģāđ€āļ™āļēāļšāļ—āļŠāļ™āļ—āļ™āļē 🔗

āļ„āđ‰āļ™āļŦāļēāļ•āļ­āļ™āļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē

āļ„āđ‰āļ™āļŦāļēāļ•āļ­āļ™āļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļēāļ‚āļ­āļ‡ Taylor & Francis

āļ•āļ­āļ™āļ­āļ·āđˆāļ™āđ† āđƒāļ™ PODCAST āļ™āļĩāđ‰

2026 BRSA Finalist Giorgi Kobidze

Meet Giorgi Kobidze, your 2026 BRSA finalist.
Harmonizing scientific innovation, patient care and regulation in advanced therapies: a podcast with Patrice Faloye by Taylor & Francis Group

2026 BRSA Finalist Richa Pandey

Meet Richa Pandey, your 2026 BRSA finalist.
In this podcast, Deborah Ojutalayo discusses targeted gene therapies for frontotemporal dementia caused by mutations in the GRN gene.

Innovating and developing tissue engineering beyond replacement: a podcast with Guillermo Ameer

In this podcast, Guillermo explores the development and diverse applications of citrate-based biomaterials, pioneered by his lab, Ameer Labs. He highlights the versatility and potential of these biomaterials, providing examples such as their use in bone and cartilage regeneration. Guillermo also deâ€Ķ
āļ‚āđ‰āļ­āļŠāļ‡āļ§āļ™āļŠāļīāļ—āļ˜āļīāđŒ: āļžāļ­āļ”āđāļ„āļŠāļ•āđŒāđāļĨāļ°āļ­āļēāļĢāđŒāļ•āđ€āļ§āļīāļĢāđŒāļ„āļ—āļĩāđˆāļāļąāļ‡āļ­āļĒāļđāđˆāđƒāļ™āļŦāļ™āđ‰āļēāļ™āļĩāđ‰āļĄāļēāļˆāļēāļ Taylor & Francis Group āļ‹āļķāđˆāļ‡āđ€āļ›āđ‡āļ™āļ—āļĢāļąāļžāļĒāđŒāļŠāļīāļ™āļ‚āļ­āļ‡āđ€āļˆāđ‰āļēāļ‚āļ­āļ‡āđāļĨāļ°āđ„āļĄāđˆāļĄāļĩāļŠāđˆāļ§āļ™āđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļŦāļĢāļ·āļ­āļĢāļąāļšāļĢāļ­āļ‡āđ‚āļ”āļĒ Listen Notes, Inc.